235 related articles for article (PubMed ID: 24978316)
1. Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.
Le Naour M; Lunzer MM; Powers MD; Kalyuzhny AE; Benneyworth MA; Thomas MJ; Portoghese PS
J Med Chem; 2014 Aug; 57(15):6383-92. PubMed ID: 24978316
[TBL] [Abstract][Full Text] [Related]
2. N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.
Yekkirala AS; Lunzer MM; McCurdy CR; Powers MD; Kalyuzhny AE; Roerig SC; Portoghese PS
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5098-103. PubMed ID: 21385944
[TBL] [Abstract][Full Text] [Related]
3. Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.
Le Naour M; Lunzer MM; Powers MD; Portoghese PS
J Med Chem; 2012 Jan; 55(2):670-7. PubMed ID: 22136373
[TBL] [Abstract][Full Text] [Related]
4. Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.
Brissett DI; Whistler JL; van Rijn RM
Eur J Pain; 2012 Mar; 16(3):327-37. PubMed ID: 22337177
[TBL] [Abstract][Full Text] [Related]
5. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
7. Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.
Yekkirala AS; Banks ML; Lunzer MM; Negus SS; Rice KC; Portoghese PS
ACS Chem Neurosci; 2012 Sep; 3(9):720-7. PubMed ID: 23019498
[TBL] [Abstract][Full Text] [Related]
8. Biased Opioid Ligands.
Faouzi A; Varga BR; Majumdar S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
[TBL] [Abstract][Full Text] [Related]
9. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
[TBL] [Abstract][Full Text] [Related]
10. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
11. Allosterism within
Jacobs BA; Pando MM; Jennings E; Chavera TA; Clarke WP; Berg KA
Mol Pharmacol; 2018 Apr; 93(4):376-386. PubMed ID: 29436492
[TBL] [Abstract][Full Text] [Related]
12. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR
J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210
[TBL] [Abstract][Full Text] [Related]
13. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
14. Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord.
Portoghese PS; Lunzer MM
Eur J Pharmacol; 2003 Apr; 467(1-3):233-4. PubMed ID: 12706480
[TBL] [Abstract][Full Text] [Related]
15. Direct and differential interaction of beta-arrestins with the intracellular domains of different opioid receptors.
Cen B; Xiong Y; Ma L; Pei G
Mol Pharmacol; 2001 Apr; 59(4):758-64. PubMed ID: 11259620
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs.
Kurasaki H; Okamoto I; Morita N; Tamura O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1601-3. PubMed ID: 20144865
[TBL] [Abstract][Full Text] [Related]
17. Molecular Interaction Between Butorphanol and κ-Opioid Receptor.
Ji J; Lin W; Vrudhula A; Xi J; Yeliseev A; Grothusen JR; Bu W; Liu R
Anesth Analg; 2020 Sep; 131(3):935-942. PubMed ID: 32701545
[TBL] [Abstract][Full Text] [Related]
18. Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.
Remesic M; Macedonio G; Mollica A; Porreca F; Hruby V; Lee YS
Bioorg Med Chem; 2018 Jul; 26(12):3664-3667. PubMed ID: 29858157
[TBL] [Abstract][Full Text] [Related]
19. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
